ANTX AN2 Therapeutics Inc

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine data poster presentations at the Infectious Disease Society of American (IDSA) IDWeek 2022 Conference from October 19-24, 2022 in Washington D.C. highlighting new data for epetraborole. AN2 Therapeutics is currently enrolling patients in its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial (NTM) lung disease.

Oral presentation pertaining to epetraborole:

Symposium: New Antimicrobials and ID Diagnostics in the Pipeline #1Title: Epetraborole: A Novel, Oral Antibiotic for NTM Lung DiseaseDate: Thursday, October 20, 2022 from 8:00-9:00am ETPresenter: Paul Eckburg, M.D.

Poster presentations pertaining to epetraborole:

Title: Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 StudiesDate: Thursday, October 20, 2022 from 12:15-1:30pm ETPoster Session: A2. PK/PD StudiesPoster Number: 593

Title: Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung DiseaseDate: Thursday October 20, 2022 from 12:15-1:30pm ETPoster Session: A2. PK/PD studies Poster Number: 619

Title: Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung DiseaseDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1697

Title: Pharmacokinetics/pharmacodynamics of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, and High Intracellular Penetration in the Intracellular Hollow Fiber System Model of Mycobacterium avium Complex Lung DiseaseDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1698

Title: Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Demonstrates Potent Efficacy and Improves Efficacy of Standard of Care Regimen Against Mycobacterium avium complex in a Chronic Mouse Lung Infection ModelDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1704

Title: In Vitro Activities of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, in Drug Combinations Against Nontuberculous Mycobacteria Including Resistance Frequency and MIC Characterization of Mycobacterium avium ATCC 700898 Epetraborole-resistant MutantsDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1712

Title: In Vitro Activities of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Against Mycobacterium avium Complex IsolatesDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1713

Title: In Vitro Drug-Drug Interaction Evaluation of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase InhibitorDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1716

Title: Tolerability and Pharmacokinetics of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease: A Phase 1b Dose-ranging and Food Effect StudyDate: Saturday, October 22, 2022 from 12:15-1:30pm ETPoster Session: A1. Antimicrobial Novel AgentsPoster Number: 1727

About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

COMPANY CONTACT:Lucy O. DayChief Financial Officerl.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:Anne Bowdidgeir@an2therapeutics.com